About Genkyotex
Genkyotex is a company based in Geneve (Switzerland) founded in 2006 was acquired by Calliditas Therapeutics in August 2020. Genkyotex has raised $51.77 million across 6 funding rounds from investors including Société Générale, Calliditas Therapeutics and Edmond de Rothschild. Genkyotex offers products and services including Setanaxib and NOX Inhibitor Platform.
- Headquarter Geneve, Switzerland
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Calliditas Therapeutics Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$51.77 M (USD)
in 6 rounds
-
Latest Funding Round
$5.61 M (USD), Post-IPO
Aug 21, 2018
-
Investors
Société Générale
& 9 more
-
Employee Count
Not available
-
Acquired by
Calliditas Therapeutics
(Aug 13, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Genkyotex
Genkyotex offers a comprehensive portfolio of products and services, including Setanaxib and NOX Inhibitor Platform.
NOX inhibitor for potential disease treatments
Platform for developing NOX-based therapeutics
Funding Insights of Genkyotex
Genkyotex has successfully raised a total of $51.77M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5.61 million completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genkyotex
Genkyotex has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Société Générale, Calliditas Therapeutics and Edmond de Rothschild.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic life sciences-focused VC firm investing in North America & Europe
|
Locked | Locked | Locked | |
|
Early-stage venture capital is invested in US and Europe.
|
Locked | Locked | Locked | |
|
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe
|
Locked | Locked | Locked |
Investor details for Genkyotex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genkyotex
Investment portfolio details for Genkyotex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genkyotex
Detailed financials for Genkyotex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genkyotex Comparisons
Peer comparison for Genkyotex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genkyotex
Detailed competitors of Genkyotex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genkyotex
Complete news archive for Genkyotex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genkyotex
Genkyotex was founded in 2006.
Genkyotex is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
Genkyotex is a funded company, having raised a total of $51.77M across 6 funding rounds to date.
Genkyotex was founded in 2006 in Geneva, Switzerland, within the biotechnology sector. Small molecule therapeutics are developed by the company to selectively target the NOX family of enzymes, addressing cardiovascular, metabolic, and neurodegenerative diseases. The lead product, GKT831, functions as a dual inhibitor of NOX4 and NOX1 and is currently in clinical development for scleroderma and non-alcoholic steatohepatitis. Operations focus on advancing these inhibitors through clinical stages.
Genkyotex offers Setanaxib and NOX Inhibitor Platform.
Genkyotex has 10 investors. Key investors include Société Générale, Calliditas Therapeutics, Edmond de Rothschild, Vesalius Biocapital Partners, and NeoMed.